Older adults vaccinated with Shingrix had about 9% less cardiovascular disease over the following seven years than adults who received Zostavax, the live-virus shingles vaccine it replaced, according to a study published in Nature Medicine. The comparison used the speed of the American switch between the two products as a natural experiment.
How the comparison worked
The United States moved from Zostavax to Shingrix in 2017 after the Food and Drug Administration approved the newer shot. Researchers took electronic health records for adults aged 60 and over, split them into a group vaccinated mostly before the transition and one vaccinated mostly after, and matched 36,460 pairs on 83 characteristics including age, diagnoses and prior prescriptions.
That design avoids a known trap in vaccine studies: people who get vaccinated tend to be healthier than those who do not, which flatters any vaccine's record. Here both groups were vaccinated, and only the product differed.
Where the benefit showed up
Over seven years, the Shingrix group spent 9% more time free of a diagnosis in the combined measure of ischaemic heart disease, ischaemic stroke and heart failure. The ratio was 0.91, with a confidence interval of 0.88 to 0.95. Ischaemic heart disease burden was 10% lower and heart failure 12% lower. Ischaemic stroke was 12% lower among men but showed no clear difference among women or in the pooled result.
The effect shrank as the years passed, which is consistent with a reaction to the shot fading rather than with a permanent change in risk. Serious adverse events were slightly less common in the Shingrix group.
What it does not prove
This is an observational comparison, not a randomised trial, and the authors calculate that an unmeasured factor would need to be 1.42 times more common in one group to explain the result away. Reactivation of the chickenpox virus is known to inflame blood vessels, so a vaccine that suppresses reactivation has a plausible route to fewer cardiac events — plausibility, not proof.
For patients over 60 the practical advice does not change: the recombinant vaccine is already the recommended product in most rich countries. What may change is how cardiologists talk about it.